TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05137821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er: YSGG laser
Description: Er: YSGG laser decontamination of infected implant surfaces to simulate peri-implantitis therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no therapy
Description: new sealed implant without any surface treatment
Study: NCT05157633

Intervention type: OTHER
Intervention: Controls
Description: questionnaire food scale: HME data collection of food survey
Study: NCT06045598

Intervention type: OTHER
Intervention: Montreal Cognitive Assessment
Description: MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.

Intervention type: OTHER
Intervention: Montreal Cognitive Assessment
Description: MoCA is a 10-minute scale that measures global cognitive skills. It includes items consisting of attention and concentration, executive functions, memory, language, visuospatial skills, abstract thinking, calculation and orientation skills. The lowest score that can be obtained from the scale is 0, and the highest score is 30. Scores of 21 and below indicate the presence of cognitive impairment.
Study: NCT05643508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) DWC202206
Description: Drug of DWC202206 A mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D) DWC202206
Description: Drug of DWC202206 A mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (D) DWC202207
Description: Drug of DWC202207 B/C mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (D) DWC202207
Description: Drug of DWC202207 B/C mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (P) DWC202206
Description: Placebo of DWC202206 A mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (P) DWC202207
Description: Placebo of DWC202207 B/C mg
Study: NCT05056974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: 10 mg/kg, weekly UB-421 during the 8-week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 10 mg/dose, twice a week for 8 weeks
Study: NCT06216366

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj pre-exposure
Description: Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj pre-exposure
Description: Sterile normal saline 0.9% administered IV as a placebo immediately before hyperbaric chamber exposure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj post-exposure
Description: Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj post-exposure
Description: Sterile normal saline 0.9% administered IV as a placebo immediately after hyperbaric chamber exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human plasma gelsolin pre-exposure
Description: rhu-pGSN administered IV at a dose of 24 mg/kg immediately before hyperbaric chamber exposure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human plasma gelsolin post-exposure
Description: rhu-pGSN administered IV at a dose of 24 mg/kg immediately after hyperbaric chamber exposure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hyperbaric chamber
Description: High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric chamber
Description: High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric chamber
Description: High-pressure profile equivalent 35 minutes at a depth of 30 meters of sea water
Study: NCT06509698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: STEP I: For the warm-up, the examiner will perform passive stretching exercises to maintain the range of motion. STEP II: The patient will receive the game instructions by the examiner. STEP III: The patient will play the Adventure games and Sport games including tennis, boxing and kicking. virtual reality (20 minutes) using Nintendo Wii®, Wii Fit game will be used to stimulate and reinforce the improvement of balance and gait and enhance the quality of life.(30) Balance game: Soccer Heading, Penguin Slides, Balance Bubble, Torso Twists, and Single Leg Stance. Motor function: Boxing, Kicking, Tennis and Bowling Aerobic Games: 2-P run, advanced step, Title city and Basic Run. Step IV: (cool-down): Same as step one.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel's exercise
Description: Frenkel's activities, which included learning how to turn around, sit down, and get up using a variety of commonplace objects like chairs, beds, or traces drawn on the floor, as well as learning how to walk with upper limb coordination. This is a typical workout regimen used in testing and rehabilitation centers. Patients engaged in the following activities, each activity time is 1.5 minutes
Study: NCT04919564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)
Description: Furosemide 2 mg/hour infusion for 12 hours since induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: NaCl 0.9% 2 cc/hour for a period of 12 hours since anesthetic induction
Study: NCT05326919

Intervention type: OTHER
Intervention: Biobanking
Description: For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

Intervention type: OTHER
Intervention: Biobanking
Description: For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

Intervention type: OTHER
Intervention: Biobanking
Description: For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.

Intervention type: OTHER
Intervention: Biobanking
Description: For storage,limited volumes of blood or bone marrow aspirate will be added to usual sampling and stored.
Study: NCT05952544

Intervention type: DRUG
Intervention: essential amino acids and keto-analogues supplementation
Description: very low protein diet plus essential amino acids and keto-analogues supplementation

Intervention type: OTHER
Intervention: low protein diet
Description: patients were on low protein diet only
Study: NCT06374290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone (Vivitrol)
Description: At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
Study: NCT05129085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the ESI group, 8mg of dexamethasone (4mg/ml) added to 1 ml of normal saline will be given (total 3ml volume).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural platelet rich plasma injection
Description: For the transforaminal epidural injection, a 22-gauge spinal needle will be inserted coaxially via a subpedicular approach to target the upper part of the foramen under fluoroscopic guidance. Correct needle position will be confirmed with appropriate contrast spread (1ml of contrast) in the anteroposterior, oblique, and lateral view. Spread of contrast delineating the nerve root together with proximal epidural spread will be accepted as indicating correct needle position. A single level injection will be performed because there are no clinical trials showing that multilevel injections is superior to single level injection, and a well-positioned injection usually spreads to multiple levels, thus achieving the effect of multi-level injection. 2ml of 1% lignocaine will be given for skin infiltration. Once correct position is confirmed, drug injectate will be administered. For the EPRP group, 3 ml of PRP will be injected. The total volume of injectate for both groups of patients is 3ml.
Study: NCT05878626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The intensity of TDCS will be 2.5 mA and the duration will be 20 mints. The intervention will be applied twice a day with a time difference of 30 minutes between the two sessions.
Study: NCT05044364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
Description: Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test.
Description: Patients with hypertensive emergency and hypertensive sub-emergency who are clinically diagnosed as unsuitable for oral antihypertensive treatment or oral antihypertensive treatment are ineffective, and require intravenous medication to quickly control their blood pressure. The qualified subjects will be randomly divided into groups according to the test protocol. The method of administration is to infuse clevidipine butyrate injection for emergency blood pressure reduction treatment to achieve rapid, effective and stable lowering of blood pressure to the target blood pressure, and prevent or reduce further damage to the target organ.
Study: NCT06486623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Black chokeberry extract in capsules with 18% standardization of the anthocyanins content
Description: Supplement group: supplement of diet - black chokeberry extract (capsules) with 18% standardization of the anthocyanins content (one capsule contained 200 mg). Each capsule also contained: chokeberry fiber, E460b magnesium salts of stearic acid (anti-caking agent), E551 silicon dioxide (anti-caking agent), hydrocypropyl methylcellulose (capsule shell) and E171 titanium dioxide (shell colour).~The producer of all capsules is MLD Biotrade in Poznan.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chokeberry fiber in capsules
Description: Placebo group: placebo product - chokeberry fiber (placebo capsules, which were made from chokeberry fiber).~The producer of all capsules is MLD Biotrade in Poznan.
Study: NCT06337552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FEED-FF
Description: 3-6 servings of any combination of the following fermented foods/day (from 1 week prior to treatment to approximately 12 weeks after the start of treatment): Yogurt, cottage cheese, kefir, kombucha, sauerkraut, and kimchi.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SUC)
Description: Standard of Care (SUC) is the treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by health care professionals. Standard of Care will comprise general healthy eating handouts that describe typical healthy foods and the suggested level of servings per day.
Study: NCT06544902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR Stress Management
Description: First Resort (FR) is an eight-week wellness program that comprises 22 modules, each lasting between 10 and 20 minutes, participants will complete modules weekly in person. Each module will teach participants about values-based goal setting/ behavioral activation, and cognitive restructuring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Participants in this group will receive one-time educational material regarding stress. The participants can review the material remotely. American Heart Association (AHA) brochures and infographics regarding chronic stress and women's health, heart disease and mental health among black women, healthy for good sleep well, among other useful resources.
Study: NCT06464315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Substrate-Only Mapping without VT Induction
Description: In this arm, invasive maps will be constructed by annotating the latest deflection and peak frequency during voltage mapping of stable intrinsic rhythm to localize areas of slow conduction. Annotated algorithms are cleared by the FDA. No VT will be purposefully induced in this experimental arm.
Study: NCT05009992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxalisib
Description: Given PO
Study: NCT05503953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSAVI
Description: Uptitation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGLS
Description: Uptitration
Study: NCT05670977

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Study product plus collagen supplement
Description: The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Study product without collagen supplement
Description: The participants in this arm will use the assigned product for 2 months, 5g one time, once a day.
Study: NCT04615871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
Study: NCT06103110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Laser therapy using low level laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Laser therapy using low level laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Laser therapy using low level laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Laser therapy using low level laser
Study: NCT05191212

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Cervical indocyanine green injection for the detection of sentinel lymph node

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: indocyanine green
Description: Cervical indocyanine green injection for the detection of sentinel lymph node
Study: NCT04621747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Battery of neurophysiological explorations
Description: Visit 1: Biometry collection: gender, age, weight, height, eye colour.~* Questionnaires : the State and Trait Anxiety Inventory and the Pain Sensitivity~* Threshold of unpleasant light brightness, mechanical sensitivity threshold (von Frey hair).~* Training to estimate unpleasantness Under nociceptive and tickling stimuli, to use the handgrip.~* Mechanical pain threshold (electronic von Frey), heat pain threshold (Medoc Pathway).~* 48 stimulations applied to the back skin, following a predetermined plan with 12 different pathways, imbricated with 4 different speeds of movement.~Visit 2 (1 to 8 days later) :~* 42 stimulations applied to the back skin, to test the effect of stimulation intensity, the side of application, continuity break of the contact, and distraction by other cutaneous stimuli. The stimuli will follow the best paradigm as identified at the previous visit.~* 12 stimulations applied to forearm, cheeks, lower limbs, also testing the effect of hairiness.
Study: NCT05802329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU200 Low Dose
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU200 Medium Dose
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU200 High Dose
Description: Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCU200 High Dose
Description: Intravitreal Injection
Study: NCT05057988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief class
Description: The participants will attend the Empowered Relief class online via Zoom. The class includes pain neuroscience education, as well as cognition, emotion, and physiologic self-regulation for people with chronic pain. Class participants will learn self-management skills and develop a personalized plan to use the skills every day. Participants will receive an audio file (Relaxation Response) post-class. The class provides patients rapid access to actionable skills for symptom management and pain relief.
Study: NCT05953064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHA-NAT
Description: Endogenous metabolite of omega-3 fatty acid docosahexaenoic acid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle control (H2O) for the intervention used in the experimental arm (DHA-NAT).
Study: NCT05654415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each enrolled patient will be subjected to two nap EEG recordings receiving in one occasion the melatonin-based solution under study at a dosage of 5 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprivation
Description: Each enrolled patient will be subjected to two nap EEG recordings,in one they will be subjected to sleep deprivation
Study: NCT04734873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 2 mg/kg + SOC
Description: IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006 1 mg/kg + SOC
Description: IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: IV placebo plus standard of care
Study: NCT04876339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation with sonification
Description: The sonification system is composed by 2 inertial sensors, a computer and a pair of bluetooth headphones connected with the computer. The sensors will be placed one per leg at the ankle and connected with Matlab software. An home-made ad-hoc software associates patient's movements with music patterns. The patient's natural rhythm is detected and used at the beginning of the intervention. The first part of each exercise is supported by a pre-recorded chord progression with a click on the background. In the second part (sonification approach) the software notices and records the contact of the heel with the ground. Each contact activates musical stimuli listened to via headphones. The steps succession will build a regular and predictable musical progression in relation to the correct sequence of steps. The exercises planned in this intervention are the same as those planned in the gait standard rehabilitation (see below).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard gait rehabilitation (without sonification)
Description: The training will be carried out without any musical support. Exercises I Phase~1. Load shift in anteroposterior standing in tandem position, left foot forward (3 minutes exercise with a short break in the middle)~2. Load shift in anteroposterior standing in tandem position, right foot forward (3 minutes exercise with a short break in the middle)~3. Left foot swing (3 minutes exercise with a short break in the middle)~4. Right foot swing (3 minutes exercise with a short break in the middle)~5. March in place (3 minutes exercise with a short break in the middle) Exercises II phase (15 minutes): the patient will perform 14 minutes of walking with a 1 minute of break in the middle (7 minutes of walking, 1 minute rest, 7 minutes of walking). In the second part of walking the patient will be asked to slightly increase the pace of the step up to the maximum possible speed.
Study: NCT04708990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delipid Extracorporeal Lipoprotein filter from Plasma
Description: As a non-pharmacological therapy, Delipid Extracorporeal Lipoprotein filter from Plasma (DELP) hase been approved by China Food and Drug Administration to treat acute stroke
Study: NCT05740787

Intervention type: OTHER
Intervention: No intervention
Description: Observation only
Study: NCT06185920

Intervention type: OTHER
Intervention: Description of severe infection
Description: Description of severe infections treated with bacteriophage in the Hospices Civils de Lyon from 2015 to 2033.